354 related articles for article (PubMed ID: 21784190)
1. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.
Matsumoto T; Ito M; Hayashi Y; Hirota T; Tanigawara Y; Sone T; Fukunaga M; Shiraki M; Nakamura T
Bone; 2011 Oct; 49(4):605-12. PubMed ID: 21784190
[TBL] [Abstract][Full Text] [Related]
2. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
[TBL] [Abstract][Full Text] [Related]
3. Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol.
Nakamura T; Takano T; Fukunaga M; Shiraki M; Matsumoto T
J Bone Miner Metab; 2013 Jul; 31(4):417-22. PubMed ID: 23575909
[TBL] [Abstract][Full Text] [Related]
4. Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis.
Hagino H; Takano T; Fukunaga M; Shiraki M; Nakamura T; Matsumoto T
J Bone Miner Metab; 2013 Mar; 31(2):183-9. PubMed ID: 23129180
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the effect of eldecalcitol and serum 25(OH)D level.
Takano T; Kondo S; Saito H; Matsumoto T;
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():124-7. PubMed ID: 24240066
[TBL] [Abstract][Full Text] [Related]
6. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
7. [Active vitamin D3 analog].
Takata S
Nihon Rinsho; 2015 Oct; 73(10):1701-5. PubMed ID: 26529933
[TBL] [Abstract][Full Text] [Related]
8. Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels.
Shiraki M; Saito H; Matsumoto T
Curr Med Res Opin; 2012 Sep; 28(9):1547-52. PubMed ID: 22794117
[TBL] [Abstract][Full Text] [Related]
9. Eldecalcitol for the treatment of osteoporosis.
Matsumoto T; Endo I
Drugs Today (Barc); 2012 Mar; 48(3):189-96. PubMed ID: 22462038
[TBL] [Abstract][Full Text] [Related]
10. Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.
Hagino H
Expert Opin Pharmacother; 2013 Apr; 14(6):817-25. PubMed ID: 23477453
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis treatment by a new active vitamin D3 compound, eldecalcitol, in Japan.
Matsumoto T
Curr Osteoporos Rep; 2012 Dec; 10(4):248-50. PubMed ID: 22918710
[TBL] [Abstract][Full Text] [Related]
12. Eldecalcitol: a review of its use in the treatment of osteoporosis.
Sanford M; McCormack PL
Drugs; 2011 Sep; 71(13):1755-70. PubMed ID: 21902297
[TBL] [Abstract][Full Text] [Related]
13. [Frontiers in vitamin D; Basic research and clinical application. The effects of eldecalcitol on bone mineral density and fracture prevention--Post hoc analysis].
Hagino H
Clin Calcium; 2011 Nov; 21(11):111-8. PubMed ID: 22040827
[TBL] [Abstract][Full Text] [Related]
14. Eldecalcitol reduces osteoporotic fractures by unique mechanisms.
Kondo S; Takano T; Ono Y; Saito H; Matsumoto T
J Steroid Biochem Mol Biol; 2015 Apr; 148():232-8. PubMed ID: 25625663
[TBL] [Abstract][Full Text] [Related]
15. [Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism].
Endo I; Matsumoto T
Clin Calcium; 2011 Nov; 21(11):103-10. PubMed ID: 22040826
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol.
Matsumoto T; Takano T; Saito H; Takahashi F
Bonekey Rep; 2014; 3():513. PubMed ID: 24818005
[TBL] [Abstract][Full Text] [Related]
17. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D sufficiency is associated with low incidence of limb and vertebral fractures in community-dwelling elderly Japanese women: the Muramatsu Study.
Nakamura K; Saito T; Oyama M; Oshiki R; Kobayashi R; Nishiwaki T; Nashimoto M; Tsuchiya Y
Osteoporos Int; 2011 Jan; 22(1):97-103. PubMed ID: 20333358
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism.
Matsumoto T; Takano T; Yamakido S; Takahashi F; Tsuji N
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):261-4. PubMed ID: 20298784
[TBL] [Abstract][Full Text] [Related]
20. [Current Topics on Vitamin D. Treatment of osteoporosis with eldecalcitol: Its therapeutic efficacy and adverse effect on renal function].
Takeuchi Y
Clin Calcium; 2015 Mar; 25(3):425-32. PubMed ID: 25716816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
